Nuvectis Pharma (NVCT) Enterprise Value (2021 - 2026)
Nuvectis Pharma (NVCT) posted Enterprise Value of -$25.1 million for Q1 2026, up 20.65% sequentially from -$31.6 million in Q4 2025, and up 16.05% YoY from -$21.6 million in Q1 2025.
Nuvectis Pharma (NVCT) Enterprise Value (2021 - 2026) Analysis & Trends
Nuvectis Pharma has reported Enterprise Value for 6 years, with the latest figure at -$25.1 million in Q1 2026.
- Quarterly Enterprise Value rose 16.05% year-over-year to -$25.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$25.1 million (up 16.05% YoY) and the FY2025 annual result came in at -$31.6 million, down 70.69% from the prior year.
- Enterprise Value advanced to -$25.1 million in Q1 2026 per NVCT's latest filing, from -$31.6 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$13.6 million in Q2 2022 and troughed at -$35.4 million in Q3 2025.
- A 5-year average of -$22.3 million and a median of -$20.8 million in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value advanced 26.36% in 2024, then sank 106.43% in 2025.
- Over 5 years, Enterprise Value stood at -$23.6 million in 2022, then advanced by 18.96% to -$19.1 million in 2023, then climbed by 3.1% to -$18.5 million in 2024, then tumbled by 70.69% to -$31.6 million in 2025, then gained by 20.65% to -$25.1 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$25.1 million, -$31.6 million, and -$35.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Nuvectis Pharma | 506.13 Mn | 506.13 Mn | - | -22.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.20 Mn |
| Mar 31, 2026 | -25.10 Mn |
| Dec 31, 2025 | -31.63 Mn |
| Sep 30, 2025 | -35.44 Mn |
| Jun 30, 2025 | -26.79 Mn |
| Mar 31, 2025 | -29.90 Mn |
| Dec 31, 2024 | -18.53 Mn |
| Sep 30, 2024 | -17.17 Mn |
| Jun 30, 2024 | -18.12 Mn |
| Mar 31, 2024 | -19.50 Mn |
| Dec 31, 2023 | -19.13 Mn |
| Sep 30, 2023 | -22.10 Mn |
| Jun 30, 2023 | -24.60 Mn |
| Mar 31, 2023 | -15.50 Mn |
| Sep 30, 2022 | -23.60 Mn |
| Jun 30, 2022 | -13.60 Mn |
| Mar 31, 2022 | -16.70 Mn |
| Dec 31, 2021 | -5.74 Mn |